London-based biotech Autifony has signed a £2.75m ($4.25m) collaboration deal with the universities of Newcastle and Manchester to develop treatments for schizophrenia. The bulk of the funding comes from a £1.9m award made to Autifony and the universities by UK innovation agency the Technology Strategy Board. As part of the collaboration, Autifony will provide its…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
